Colistin monotherapy versus combination therapy for carbapenem-resistant organisms
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
KS Kaye, D Marchaim, V Thamlikitkul, Y Carmeli… - NEJM …, 2022 - europepmc.org
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms.
KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2023 - scholarlyworks.beaumont.org
METHODS: The OVERCOME (Colistin Monotherapy versus Combination Therapy) trial was
an international, randomized, double-blind, placebo-controlled trial. We randomly assigned …
an international, randomized, double-blind, placebo-controlled trial. We randomly assigned …
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2023 - iris.unicampania.it
Background: Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
[HTML][HTML] Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
KS Kaye, D Marchaim, V Thamlikitkul, Y Carmeli… - NEJM …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Pneumonia and bloodstream infections (BSI) due to extensively drug-
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2022 - scholarlycommons.henryford.com
BACKGROUND: Pneumonia and bloodstream infections (BSI) due to extensively drug-
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
KS Kaye, D Marchaim, V Thamlikitkul… - NEJM …, 2022 - scholarlyworks.beaumont.org
BACKGROUND Pneumonia and bloodstream infections (BSI) due to extensively drug-
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …
resistant (XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …